CLINICAL TRIALS PROFILE FOR CASPOFUNGIN ACETATE
✉ Email this page to a colleague
All Clinical Trials for Caspofungin Acetate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00008359 ↗ | Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment | Completed | National Cancer Institute (NCI) | Phase 3 | 2000-08-01 | RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation. It is not yet known whether caspofungin acetate or amphotericin B liposomal is more effective for treating these side effects. PURPOSE: Randomized phase III trial to compare the effectiveness of caspofungin acetate with that of amphotericin B liposomal in treating patients who have persistent fever and neutropenia after receiving anticancer therapy. |
| NCT00008359 ↗ | Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment | Completed | Memorial Sloan Kettering Cancer Center | Phase 3 | 2000-08-01 | RATIONALE: Caspofungin acetate or amphotericin B liposomal may be effective in preventing or controlling fever and neutropenia caused by chemotherapy, bone marrow transplantation, or peripheral stem cell transplantation. It is not yet known whether caspofungin acetate or amphotericin B liposomal is more effective for treating these side effects. PURPOSE: Randomized phase III trial to compare the effectiveness of caspofungin acetate with that of amphotericin B liposomal in treating patients who have persistent fever and neutropenia after receiving anticancer therapy. |
| NCT00020527 ↗ | Caspofungin Acetate in Treating Children With Fever and Neutropenia | Completed | National Cancer Institute (NCI) | N/A | 2001-03-01 | RATIONALE: Giving caspofungin acetate may be effective in preventing or controlling fever and neutropenia caused by chemotherapy or bone marrow transplantation. PURPOSE: Clinical trial to study the effectiveness of caspofungin acetate in treating children who have fever and neutropenia caused by a weakened immune system. |
| NCT00082524 ↗ | Documented Candida or Aspergillus Infections in Pediatric Patients (0991-043) | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2004-04-01 | This study is an open label, noncomparative study using an investigational agent for the treatment of documented Candida or Aspergillus infections in pediatric patients (ages 3 months-17 years). |
| NCT00082537 ↗ | MK0991 Versus Amphotericin B for Empirical Therapy in Febrile, Neutropenic Pediatric Patients (0991-044) | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2004-04-01 | This study is a double-blind, randomized study of MK0991 versus liposomal amphotericin B in the empirical treatment of pediatric patients (ages 2 through 17 years) who have an absolute neutrophil count (ANC) below 500/microliter and who have fever despite broad antibiotic coverage. Such patients would be candidates for empirical therapy with an intravenous anti-fungal agent. |
| NCT00083343 ↗ | Caspofungin for the Treatment of Non-blood Candida Infections (0991-045) | Completed | Merck Sharp & Dohme Corp. | Phase 2 | 2004-05-01 | Candida is the most common fungal pathogen identified in hospitalized patients. This study will seek to enroll adult patients (18 years of age or older) with invasive Candida infections (involving deep tissues and organs). The study will not enroll patients whose only site of Candida infection was the bloodstream. Patients that fulfill all study entry criteria will receive a single daily dose of caspofungin. Caspofungin, an intravenous echinocandin antifungal agent, is already approved for the treatment of invasive candidiasis. The dosage strength and duration of caspofungin will be individualized for each patient based on disease, severity of disease and extent of infection. |
| NCT00110045 ↗ | Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant | Completed | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 | 2005-02-01 | RATIONALE: Antifungals, such as caspofungin acetate, may be effective in treating fungal infections caused by chemotherapy or stem cell transplant. PURPOSE: This phase II trial is studying how well caspofungin acetate works as first-line treatment for aspergillosis in patients with hematologic cancer or in patients who have undergone a stem cell transplant. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Caspofungin Acetate
Condition Name
Clinical Trial Locations for Caspofungin Acetate
Trials by Country
Clinical Trial Progress for Caspofungin Acetate
Clinical Trial Phase
Clinical Trial Sponsors for Caspofungin Acetate
Sponsor Name
